Lack of Efficacy of Combined Antiangiogenic Therapies in Xenografted Human Melanoma

Cerdeira, C. R., Gregorio, M. C., Barcenas, A. L., Blanco, E. S., Blanco, B. S., Fabbrocini, G., Bardhi, B., Sinani, A., & Guzman, R. A. (2017). Advances in Immunotherapy for Melanoma: A Comprehensive Review. Mediators of Inflammation, 2017(), 1-14. https://doi.org/10.1155/2017/3264217
Voskoboynik, M., & Arkenau, H. T. (2014). Combination Therapies for the Treatment of Advanced Melanoma: A Review of Current Evidence. Biochemistry Research International, (2014), f1-9. https://doi.org/10.1155/2014/307059
Ganzach, Y., & Leshno, M. (2007). On the Appropriateness of Appropriateness Judgments: The Case of Interferon Treatment for Melanoma. Judgment and Decision Making, 2(1), 70-78. https://www.airitilibrary.com/Article/Detail?DocID=19302975-200702-201011090003-201011090003-70-78
Viola, J. R., Rafael, D. F., Wagner, E., Besch, R., & Ogris, M. (2013). Gene Therapy for Advanced Melanoma: Selective Targeting and Therapeutic Nucleic Acids. Journal of Drug Delivery, 2013(), 304-318. https://doi.org/10.1155/2013/897348
Lemech, C., & Arkenau, H. T. (2012). Novel Treatments for Metastatic Cutaneous Melanoma and the Management of Emergent Toxicities. Clinical Medicine Insights: Oncology, (), 53-66. https://doi.org/10.4137/CMO.S5855